IPA Company Profile and Key Details

Q: Who are the executives of IPA?

Dr. Ilse RoodinkChief Scientific OfficerDr. Roland RomijnHead of Gen. Operations of the Utrecht site of IPA (Europe)Dr. Jennifer Lynne Bath Ph.D.Chief Executive Officer, Pres & Non-Independent DirectorMr. David E. OrtonChief Operating OfficerMr. Brad McConnChief Financial OfficerMs. Carla DahlVice President of MarketingDr. Barry Neil DuplantisVice President of Client Relations

NASDAQ : IPA

ImmunoPrecise Antibodies

$1.62

0.04+2.53%

At Close 4:00 PM

Not Actively Trading

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ImmunoPrecise Antibodies Ltd. (IPA) stock surged +2.53%, trading at $1.62 on NASDAQ, up from the previous close of $1.58. The stock opened at $1.65, fluctuating between $1.56 and $1.65 in the recent session.

Stock Snapshot

1.58

Prev. Close

74.77M

Market Cap

1.56

Day Low

-2.4545454545454546

P/E Ratio

-0.66

EPS (TTM)

-0.55

Cash Flow per Share

1.65

Open

46.15M

Number of Shares

1.65

Day High

90.88%

Free Float in %

1.93

Book Value

55.67K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Oct 21, 2025	1.58	1.62	1.57	1.57	44.85K
Oct 20, 2025	1.65	1.65	1.56	1.64	356.26K
Oct 17, 2025	1.65	1.65	1.50	1.58	636.75K
Oct 16, 2025	1.77	1.78	1.61	1.64	610.84K
Oct 15, 2025	1.80	1.84	1.68	1.71	693.5K
Oct 14, 2025	1.88	1.90	1.78	1.80	596.66K
Oct 13, 2025	1.87	1.92	1.84	1.90	500.69K
Oct 10, 2025	2.02	2.02	1.80	1.81	645.09K
Oct 09, 2025	2.05	2.19	1.95	1.97	1.82M
Oct 08, 2025	1.89	1.95	1.82	1.87	324.79K
Oct 07, 2025	1.83	1.95	1.80	1.88	713.4K
Oct 06, 2025	1.72	1.83	1.66	1.83	592.23K
Oct 03, 2025	1.77	1.79	1.66	1.69	624.18K
Oct 02, 2025	1.79	1.82	1.70	1.77	476.17K
Oct 01, 2025	1.75	1.84	1.72	1.78	394.48K
Sep 30, 2025	1.72	1.79	1.67	1.75	510.16K
Sep 29, 2025	1.80	1.89	1.69	1.73	676.95K
Sep 26, 2025	1.78	1.85	1.77	1.80	416.96K
Sep 25, 2025	1.90	1.94	1.75	1.77	737.87K
Sep 24, 2025	1.95	2.04	1.88	1.89	679.54K

Contact Details

Austin, BC V8Z 7X8

Canada

https://www.ipatherapeutics.com 250 483 0308

About Company

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Stock Peers

ARGX

3.05+0.36%

argenx SE$840.95 REGN

-2.07-0.27%

Regeneron Pharmaceuticals, Inc.$771.87 MDGL

-1.39-0.24%

Madrigal Pharmaceuticals, Inc.$582.34 UTHR

-8.94-1.80%

United Therapeutics Corporation$487.25 VRTX

-0.38-0.08%

Vertex Pharmaceuticals Incorporated$453.36 ALNY

0.4+0.10%

Alnylam Pharmaceuticals, Inc.$397.65 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-2.28-0.77%

Praxis Precision Medicines, Inc.$294.74 KRYS

-1.34-0.54%

Krystal Biotech, Inc.$246.54 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) closed at $1.62 USD, gaining $0.04 (2.53%) from the previous close of $1.58. The stock is currently mid-range between its 52-week high and low $0.27 and $3.25. With a market capitalization of about $74.77 million, ImmunoPrecise Antibodies Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 2.91 million shares, volume is running light vs its 52-week average. Headquartered in Austin, BC, ImmunoPrecise Antibodies Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer Lynne Bath, the company employs approximately 72 people and listed since January 07, 2002. ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -11.31%, SMA50 8.82%, SMA200 149.75%). The stock’s 14-day RSI is 47.1 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.23% below its high and over 666.67% above its low.

Valuation Metrics

ImmunoPrecise Antibodies Ltd. trades at a P/E ratio of -3.51, slightly below the S&P 500 average, with a price-to-sales ratio of 4.57 and a price-to-book ratio of 4.94 trading at moderately above to book value. The P/FCF stands at -10.66, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

ImmunoPrecise Antibodies Ltd. generated EPS of -$0.67 over the past year. Five-year average earnings growth is -19.06%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.04. Next year's EPS is expected at $40.23. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $3.00. The high target offers 332.1% upside. The low target suggests 85.19% downside. The mean target is $5.00. This offers 208.64% upside. ImmunoPrecise Antibodies Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended September 15, 2025, missed forecasts by 62.4%. The prior quarter beat by 100.0%. Over the last six quarters, Apple has recorded several small beats. These include 420.0% in July 29, 2024.

Shareholding & Insider Activity

ImmunoPrecise Antibodies Ltd. has 46.15 million shares outstanding. The public float is 41.95 million shares, elevated short interest at 1.59% of float. This equals 725.31 thousand shares. The short ratio is 0.35 days. Institutional investors hold 9.53% of the float. Insiders own 9.07%.

Financial & Profitability Overview

Over the trailing twelve months, ImmunoPrecise Antibodies generated $24.52M in revenue, or $0.73 per share. Gross margin was 55.25%, operating margin -49.74%, and net profit margin -123.30%. Returns are negative, with ROA at -50.40% and ROE at -89.13%.
On valuation metrics, ImmunoPrecise Antibodies trades at a P/E of -3.51, P/S of 4.57 and P/B of 4.94. The current ratio is 2.17 and quick ratio is 2.14. Operationally, the company’s inventory turnover is 18.51 and cash conversion cycle is -61.20 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.18, supported by a cash flow-to-debt ratio of -2.36.

Quarterly Financial Highlights

For the quarter ended Apr 30, 2025, ImmunoPrecise Antibodies posted revenue of $24.52M, down slightly from $24.52M in the prior quarter. Gross profit was $13.55M (margin 55.25%). Operating income was - $12.20M (margin -49.7%). Net income was- $30.23M (EPS - $0.91).
The company ended the quarter with $3.46M in cash and short-term investments, a total debt of $13.68M, and net debt of $10.22M. Total assets were $59.99M, with equity of $33.92M. Financials further reflected weakness, with operating cash flow of - $19.83M, free cash flow of - $21.33M, and capital expenditures of - $1.50M.

Price Forecast & Outlook

Our AI price prediction model suggests that ImmunoPrecise Antibodies Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.18%, with price expected at $1.52 by November 04, 2025, within a range of $1.38 to $1.69 3-Month Outlook: Projected rise of 163.69%, reaching $4.14 by January 19, 2026, with a range of $4.10 to $4.17. 1-Year Outlook: Projected gain of 947.77%, with price at $16.45 by October 21, 2026, within a range of $17.12 to $18.11.

Key Takeaways

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) shares are up 402.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ImmunoPrecise Antibodies Ltd. trading at a premium to the broader market with a P/E of -3.51. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $7.50, suggesting 377.71% upside. Our AI forecast model points to short-term weakness (-3.18% over two weeks), a medium-term rise (163.69% over three months), and a longer-term gain (947.77% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ImmunoPrecise Antibodies Ltd. (IPA) stock price?

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) stock price is $1.62 in the last trading session. During the trading session, IPA stock reached the peak price of $1.65 while $1.56 was the lowest point it dropped to. The percentage change in IPA stock occurred in the recent session was 2.53% while the dollar amount for the price change in IPA stock was $0.04.

IPA's industry and sector of operation?

The NASDAQ listed IPA is part of Biotechnology industry that operates in the broader Healthcare sector. ImmunoPrecise Antibodies Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IPA?

Dr. Ilse Roodink
Chief Scientific Officer
Dr. Roland Romijn
Head of Gen. Operations of the Utrecht site of IPA (Europe)
Dr. Jennifer Lynne Bath Ph.D.
Chief Executive Officer, Pres & Non-Independent Director
Mr. David E. Orton
Chief Operating Officer
Mr. Brad McConn
Chief Financial Officer
Ms. Carla Dahl
Vice President of Marketing
Dr. Barry Neil Duplantis
Vice President of Client Relations

How IPA did perform over past 52-week?

IPA's closing price is 500% higher than its 52-week low of $0.27 where as its distance from 52-week high of $3.25 is -50.09%.

How many employees does IPA have?

Number of IPA employees currently stands at 72.

Link for IPA official website?

Official Website of IPA is: https://www.ipatherapeutics.com

How do I contact IPA?

IPA could be contacted at phone 250 483 0308 and can also be accessed through its website. IPA operates from 3204–4464 Markham Street, Austin, BC V8Z 7X8, Canada.

How many shares of IPA are traded daily?

IPA stock volume for the day was 55.67K shares. The average number of IPA shares traded daily for last 3 months was 2.91M.

What is the market cap of IPA currently?

The market value of IPA currently stands at $74.77M with its latest stock price at $1.62 and 46.15M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	72
Beta	0.49
Sales or Revenue	$24.52M
5Y Sales Change%	0.098%
Fiscal Year Ends	April
Sector	Healthcare
Industry	Biotechnology

IPA Company Profile and Key Details

ImmunoPrecise Antibodies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics